Dr. Epitropoulos highlights the treatments for dry eye disease secondary to meibomian gland dysfunction.
This activity is supported by an unrestricted educational grant from Bausch + Lomb.
Treatments for MGD
Media formats available:
Details
Presenters
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize the latest data on treatments for MGD
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Alice T. Epitropoulos, MD, FACS
Private practice
Ophthalmic Surgeons & Consultants of Ohio
and the Eye Center of Columbus, Ohio
Clinical Associate Professor
The Ohio State University
Wexner Medical Center
Columbus, OH
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
Alice T. Epitropoulos, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisor: Oyster Point Pharma. Consultant: Aldeyra, Allergan/AbbVie, Bausch + Lomb, BioTissue, Bruder, Dompé, EyePoint Pharmaceuticals, Imprimis, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Physician Recommended Nutriceuticals, Sight Sciences, Sun Pharma, Tarsus Pharmaceuticals, and Visus. Grant/Research Support: AimMax Therapeutics, Bausch + Lomb, and Sylentis. Primary Investigator: Third phase 3 FDA clinical trial for Dextenza. Property Right/Patent Holder: Hilco. Speaker’s Bureau: Allergan/AbbVie, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, and Sun Pharma.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Bausch + Lomb.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Andrew R. Harrison, MD
Kian Eftekhari, MD
Andrew G. Lee, MD
Wendy W. Lee, MD
Nicholas Robert Mahoney, MD
Amina Malik, MD
Prem S. Subramanian, MD, PhD
Jeremiah Tao, MD, FACS
Blake K. Williamson, MD, MPH, MS
Brett Mueller, DO, PhD
Taj Nasser, MD
Julie Marie Schallhorn, MD, MS
Evan D. Schoenberg, MD
F. Beau Swann, MD, MS
Rahul S. Tonk, MD, MBA
William F. Wiley, MD
- CME/CE Broadcast Replay
KOL Knockout™ - Cataract Edition: More than Best Corrected Visual Acuity: Meeting Patient Refractive Expectations - Round 3
1.50 creditsBlake K. Williamson, MD, MPH, MS
Evan D. Schoenberg, MD
Rahul S. Tonk, MD, MBA
William Wiley, MD
- CME/CE Broadcast Replay
KOL Knockout™ - Cataract Edition: More than Best Corrected Visual Acuity: Meeting Patient Refractive Expectations - Round 2
1.50 creditsBlake K. Williamson, MD, MPH, MS
Brett Mueller, DO, PhD
Taj Nasser, MD
Evan D. Schoenberg, MD
